Publish time: 2022-03-28 00:00:00
The present disclosure further provides methods of using the inventive compounds, and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof, as therapeutics for the treatment of a proliferative diseases such as cancer (e.g., lung cancer or breast cancer) in a subject in need thereof. In some embodiments, the subject has lung cancer, e.g., non-small cell lung cancer. In some embodiments, the subject has a lung cancer that is resistant to drug treatment, for example, resistant to a tyrosine kinase inhibitor, including those described herein. In some embodiments, the subject has breast cancer, for example, a breast cancer that is negative of estrogen receptor (ER), progesterone receptor (PR) and/or Her2/neu. In some examples, the subject is a human patient having triple-negative breast cancer (negative of estrogen receptor (ER), progesterone receptor (PR) and Her2/neu).
Novel compounds for treatment lung cancer that is resistant to drug treatment and for treatment breast cancer that is negative of estrogen receptor, progesterone receptor and/or Her2/neu.
28A-1041220
US 10,765,681; TWI 722106
Cancer treatment
Infectious disease treatment
Chi-Huey Wong, Jim-Min Fang, Ting-Jen Cheng, Ling-Wei Li, Pan-Chyr Yang, and Szu-Hua Pan
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Request for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office

Purine Compounds possessing anticancer activity